English

HC Andersen Capital Events 25/4: Meet the management in ExpreS2ion Biotechnologies and NeoDynamics

Report this content

HC Andersen Capital is today hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.

Expres2ion Biotechnologies - Rights Issue
Expres2ion Biotechnologies have announced a new share issue with preferential rights for the Company’s existing shareholders. The Rights Issue is fully covered by subscription undertakings. The gross proceeds of approximately SEK 73 million will primarily be used as to advance the breast cancer vaccine candidate ES2B-C001 to completion of the preclinical safety studies, advance other pipeline development projects, including within Influenza and Malaria, and support the strategic CRO business and invest in core technologies and IP to strengthen competitive edge.  

In the event the primary focus will be on the options you as investor have with preferential rights have and the nuts and bolts of a preferential rights issue that is fully covered.  

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines for infectious diseases and cancer. Currently the company is developing vaccines against Covid-19, breast cancer and Influenza.

Monday the 25th of april 11:00 - 11:30

Register here.

NeoDynamics - Latest development
Meet NeoDynamics’ CFO Aaron Wong, who will give an update on the latest development in the company.

  • NeoDynamics recently made a rights issue with net proceeds of 69 mio. SEK – What should the funds be used for?  
  • US market scalability and volume.  
  • What should investors expect from the SBI/ACR Breast Imaging Symposium in Savannah, Georgia, taking place on May 16-19?  

NeoDynamics AB is a Swedish medical technology company dedicated to improving diagnostics and treatment of cancer. The company has created an innovative precision biopsy system called NeoNavia. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is being evaluated for breast cancer diagnosis in leading clinics in Great Britain, Germany, and Sweden. More than 500 patients have already been tissue sampled by the biopsy system which has now been launched on the market.  

NeoDynamics is listed on Spotlight Stock Market in Sweden but will change to Nasdaq First North Growth Market the 2nd of May 2022.

Monday the 25th of april 13:00 - 13:30

Register here.


*Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies and NeoDynamics through a Digital IR/Corporate Visibility agreement.
 

Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
 

HC Andersen Capital digitializes the relation between listed companies and investors. We work long-term for companies that want more visibility in the market.  #DemocraticIR - HC Andersen Capital works to democratize access to the financial markets.

Subscribe